Cord blood cell therapy trial suspended
Article Abstract:
Umbilical cord blood stem cell therapies used in the treatment of blood cancers are forging ahead, however, suspension of a phase 1/2 trial of a non-matched cord blood therapy by Viacell following adverse events has shaken investors confidence. This has forced major investors to reevaluate the risks associated with their therapeutic strategy and increasing scrutiny on other pharmaceutical firms.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
It came from beneath the sea
Article Abstract:
Pelagibacter ubique, is a member of a bacterial grouping called SAR 11, so called because of its discovery in the Sargasso Sea that is the most prevalent life form in the marine environment. The first member of the SAR 11 clade to be successfully cultured, Pelagibacter ubique has a genome that, despite its small size, encodes the genes necessary for the biosynthesis of all 20 amino acids.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Pharma consolidates its grip on post-antibody landscape
Article Abstract:
The pharma industries are switching rapidly to the use and development of fully human antibodies and their fragments as these offer numerous advantages in terms of delivery routes and manufacturing and are highly stable molecules with low molecular weight. The antibody development strategies and achievements of a number of famous pharma companies are discussed in the article.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Possible LCS, international sales: BAE eyes expanded markets for ship protection gun. Exec: Boeing worries about homeland security tech liability
- Abstracts: Auspicious antigens. Immunotherapy dispenses with tumor antigens. Immunosuppressive networks in the tumor environment and their therapeutic relevance
- Abstracts: Empowering the inventor: The case of monoclonal antibodies. Flexibility: The guiding principle for antibody manufacturing
- Abstracts: Recombinant protein therapeutics - success rates, market trends and values to 2010. Monoclonal antibodies in the clinic
- Abstracts: Publicity and the regulator: Striking a balance. Mind the cap. E&Y faces Equitable grilling